TAKTakeda Pharmaceutical Co Ltd (ADR)
$17.21
$0.16
(0.94%)
Pre-Market
EarningsJul 30
Mkt Cap$54.24B
Vol1,012.00
Takedas Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of...
Business Wire
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.
Zacks
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today announced a groundbreaking collaboration aimed at strengthening Indonesias plasma ecosystem and...
Business Wire
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
Zacks
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
ADMA shares rebound 13.5% in a month after a steep decline, even as lowered 2026 guidance and IG market competition continue to weigh on sentiment.
Zacks
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
Zacks
Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data?
Is Takeda Pharmaceutical Company Limited (TAK) Stock Positioned for Growth After Strong LATITUDE Atlas Study Data...
Yahoo! Finance: News
Takeda Names Julie Kim CEO As Christophe Weber Retires
(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK, 4502.T) announced on Wednesday that it has appointed Julie Kim as President and CEO, completing an 18-month leadership transition...
Nasdaq News: Markets
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK) today announced that Julie Kim was officially appointed Takedas Representative Director, President and Chief Executive Officer. During the 150th Annual General Meeting of Shareholders, which took place in Osaka, Japan...
Business Wire
Denali to Sell Priority Review Voucher for $195M Cash Boost
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
Zacks
<
1
2
...
>
Advertisement|Remove ads.
Latest TAK News
ViewTakedas Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Business Wire
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Zacks
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
Business Wire
MSTR9
18
ORCL54
34
SPCX17
9Advertisement|Remove ads.